Gilead Holding Up at $33 on Exhaustion of Negativity

Gilead (GILD) has finally caught some bids today up 0.5% on a volume of 23M (Ave. volume 12M) shares! Among the supporters of the stock are Leerink Swann who maintain their “Market Outperform” and price target of low 40’s and JPMorgan who reiterate their “Overweight”and reduced target of  $5 from $55. JPMorgan says the Street […]

Continue Reading 0

Earnings Reports:Gilead (GILD) and Meridian (VIVO) Get Mixed Reviews

Gilead (GILD) Down on Missed Estimates-Is the  Worst Finally Over for the Stock? Despite its stock being down over 30% from Q1 highs and earnings downgrades in April as a fallout from healthcare reform, the Company still disappoints Wall Street with Net Income of $712.1M or 79 cents a share up from $571M or 61 […]

Continue Reading 0

Funding of Technology Start-Ups and Campus Incubators

The story below published in the June 25 NYT merits further development. We are compiling data on other successful University start-ups and incubators such as the M.I.T deals in the article. The boom in campus incubators with a focus on commercializing inventions and nurturing start-up companies really got accelerated in early 2000 following the 90’s […]

Continue Reading 0

News Update: Hospital Costs Can Go Up as a Result of Bad Trades

The trading mentality and derivatives debacle that  infected our financial system has impacted the financial health of hospitals. Who knew hospital management could do interest- rate swaps? They got crushed and now they are suing Wall Street firms. See WSJ story below. Hospitals Sue Wall Street Over Trades – WSJ.com

Continue Reading 0

Biomarker Diagnostics Drive Personalized Medicine #1 Update

But Path to Market is Still Rife with Hurdles Convergence of Genomics and Medicine At the 2010 BIO Conference in Chicago with about 15,000 attendees there were ten Breakout Sessions on Biomarkers (BM) encompassing Intellectual Property, commercialization, reimbursement, drug development and diagnostics. This explosive new technology niche is a nascent paradigm for exploiting breakthroughs in […]

Continue Reading 0

Auxilium (AUXL) Holding Up After Barron’s “Not-So-Great Math”

Auxilium (AUXL) shares held up today ($24.85 up 0.65%) after a June 28 article questioned the valuation of the stock. Revenues for the last quarter were $45.5M primarily from its Testim testosterone gel, with a loss of $8.6M.Analysts have high expectations for a recently approved drug Xiaflex for treatment of Dupuytren’s disease and  reduce surgery […]

Continue Reading 0

Oncology Pipeline Update

Here is an update on Oncology Pipelines courtesy of Linda Pullan (lpullan@msn.com), a consultant who follows the sector. www.PullanConsulting.com Pfizer (PFE), Roche (RHHBY) and Novartis (NVS) are predicted to launch the most drugs. Some Pharma Companies Need to In-License in Oncology Now by Linda Pullan___________________________________________ Pharma and Biotech companies that can’t replace or outpace current […]

Continue Reading 0

Supergen(SUPG) in a Rally Mode at $2.43;Reiterate Buy

Supergen (SUPG) has been moving up steadily over the past few days since its low in the $2.10+ range this week.SUPG is in the Rayno Life Science Portfolio. The April 15,2010 high was $3.72.The balance sheet is strong with over $100M in cash,Shareholder Equity of $106M and no debt. Market Cap is $147M. Revenue for […]

Continue Reading 0

Post-ASCO Doldrums

Market Risk is Up-Speculation Is Off-Look for Value The news out of ASCO was not that new and exciting but it is even harder to find anything positive to write about three weeks later. Investors are “hiding out”. The overall market has cooled down from the recent rally and macro news has not been good: […]

Continue Reading 0

Multinational Drug Stocks and the Euro ETF(FXE)

Large Cap drug stocks have rallied over the past week as the market was up overall but also because the Euro was up 3% over the past 4 days. Is the correlation there? Well look at these charts tracking drug multinationals and the Euro through the ETF FXE. Pfizer (PFE) and Abbott (ABT) track well […]

Continue Reading 0